Skip to main content
Premium Trial:

Request an Annual Quote

GenomeQuest Names New CFO, O'Connor Named VP of Sales and Marketing at SQI, Utterman Joins Ludesi Board

NEW YORK (GenomeWeb News) - GenomeQuest has appointed Deirdre Aubuchon to be the company’s chief financial officer. Aubuchon formerly was CFO and chief operating officer at Deploy Solutions and she was VP of finance at ZEFER, where she oversaw that company’s IPO.

Signature Genomic Laboratories has named Roger Schultz to serve as laboratory director. Schultz formerly was associate director of cytogenetics of Veripath Laboratories at the University of Texas Southwestern, where he worked for 15 years on research focused on genome stability and DNA repair mechanisms.

SQI Diagnostics has appointed Thomas O’Connor to be senior VP of sales and marketing. O’Connor formerly was an executive in sales and business development at Luminex, Beckman Coulter, and Exagen Diagnostics.

Xenomics said last week that Gianluigi Longinotti-Buitoni will cease to serve as the company’s executive chairman but will remain in his post as chairman of the board of directors. The board set up a committee to search for a CEO with experience relevant to developing and marketing diagnostic tests.
Xenomics also said it is requiring that Longinotti-Buitoni invest up to $1 million in the company to purchase up to 1,818,181 units, each unit consisting of one share of common stock and one warrant, at a purchase price of $0.55 per unit.

Berkeley HeartLab has tapped Christopher Hall to serve as chief business officer, succeeding Frank Ruderman, the former CEO and chairman who is leaving the company now that it has been integrated into Celera, which purchased BHL a year ago. Ruderman will continue to consult for Celera during a transition period.
Hall has held several executive roles at BHL, and he has been chief clinical operations officer since 2005.

Pathwork Diagnostics has appointed Fletcher Payne to be chief financial officer and Mark McDonough to be VP of US sales. Fletcher Payne previously was VP and CFO at Plexxikon, and he formerly worked at Dynavax Technologies, Cell Genesys, Sun Microsystems, and IBM.
McDonough has been VP of US sales at US Labs, a division of Laboratory Corporation of America, and he was involved in sales management at Ventana Medical Systems.

Lars Eric Utterman has been named chairman of Ludesi’s board of directors, the company said this week. Utterman previously was an executive at GE Healthcare, Amersham Pharmacia, and at Boehringer Mannheim. He now serves as president and CEO of Gyros AB, and he is chairman of the board at IonGate Biosciences.

Serigene has appointed Tom Russell to its scientific advisory board. Russell is founder, CSO, and VP of research and development of Russell Biotech. He also served as director of research and technology at Coulter Corporation, VP of reagent development at Immunicon, and he has invented cell selection and flow cytometry technologies.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.